Compare ACADIA Pharmaceuticals Inc. (ACAD) vs Cytokinetics Inc (CYTK) Price & Performance
Price performance
Price movement over the last 24 hours
Key statistics
Key statistics
ACADIA Pharmaceuticals Inc. vs Cytokinetics Inc — how do they compare? ACADIA Pharmaceuticals Inc. trades at $25.82 (market cap $4.49B), while Cytokinetics Inc trades at $83.62 (market cap $11.62B). The key difference: Cytokinetics Inc is far larger — about 2.6× ACADIA Pharmaceuticals Inc.'s market cap, and Cytokinetics Inc is trading nearer its 52-week high, ACADIA Pharmaceuticals Inc. nearer its low. Which is the better fit depends on your goals.
| ACAD | CYTK | |
|---|---|---|
Market Cap | $4.49B | $11.62B |
Sector | Health | Technology |
52-Week High | $28.06 | $87.26 |
52-Week Low | $20.06 | $33.23 |
Enterprise Value | $3.69B | $12.09B |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
ACAD trades at $26.20, up 0.89% today, with strong analyst consensus (70% buy ratings) and a $33.67 price target. Recent CHMP recommendation for Daybue in Europe (Business Wire, June 26, 2026) drove positive sentiment. The stock shows bullish technical signals with moving averages supporting upside, though RSI levels indicate overbought conditions. Fundamentally, revenue grew to $1.07B in 2025 with a robust net income margin of 34.3%, though Q1 2026 earnings missed expectations.
Outlook remains positive given commercial execution and pipeline catalysts like remlifanserin data, but risks include earnings volatility and regulatory dependencies. The stock offers growth potential in neuropsychiatry markets, balanced by execution risks in clinical trials and competitive pressures.
CYTK trades at $85.57, down 1.06% on the day, with a bullish technical signal from moving averages and strong analyst support. The company reported a net loss of $784.96 million in 2025, with revenue of $88.04 million, but recent news highlights the European launch of MYQORZO and upcoming clinical data presentations at the ESC Congress 2026, indicating growth potential.
The outlook for CYTK is driven by product launches and clinical milestones, but high valuation (P/S 98.09) and persistent losses pose risks. Analyst consensus is overwhelmingly bullish with a $110.60 price target, though investors must weigh the speculative nature against execution risks and cash burn.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About ACADIA Pharmaceuticals Inc.
Acadia Pharmaceuticals is a biotechnology company that develops and commercializes biopharmaceutical products to address central nervous system disorders. The company aims to discover small molecule drugs that address disorders such as Parkinson's, Alzheimer's, and schizophrenia. Acadia also seeks to in-license or acquire complementary products and candidates. The company's patent applications claim proprietary technology, including novel methods of screening and chemical synthetic methods, novel drug targets, and novel compounds identified using its technology.
Read more on ACAD →About Cytokinetics Inc
Cytokinetics is a biopharmaceutical company focused on muscle biology. It develops muscle activators and inhibitors as potential treatments for debilitating diseases where muscle performance is compromised or declining.
Read more on CYTK →
